Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06608381

Comparison Partial Versus Total Omentectomy in Minimal Invasive Distal Gastrectomy for cT3/4a Gastric Cancer (KLASS-10)

For advanced gastric cancer, surgical resection is the only curable therapeutic strategy. According to minimally invasive approach is adopted in various field of oncologic surgery, laparoscopic gastrectomy with lymph node dissection is becoming a standard not only for early gastric cancer but also for advanced gastric cancer.

The greater omentum is an organ is known to play a role in removing bacteria in the abdominal cavity as a primary defense. Complete resection of the greater omentum has been considered essential to ensure the elimination of micrometastasis during surgery for advanced gastric cancer. However, the oncological effect of total omentectomy is still lack of evidence. Especially in minimal invasive gastrectomy, total omentectomy procedure is known to increases the operating time, increase the risk of bleeding, colonic injury, and postoperative complications such as intra-abdominal abscess, ascites, anastomotic leakage, ileus and wound infections. Therefore, in the case of minimal invasive surgery in early gastric cancer, omentectomy is omitted usually or routinely. Partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Advanced energy devices facilitate partial omentectomy during laparoscopic gastrectomy.

According to the Japanese Gastric Cancer Treatment Guidelines, partial omentectomy (omentum preservation) is feasible for T1 or T2 tumors, and total omentectomy is recommended for clinical T3 or deeper tumors. However, the National Comprehensive Cancer Network(NCCN) guideline suggests total omentectomy and the European Society for Medical Oncology(ESMO) guideline does not mentioned about it.

It is still controversial whether total omentectomy should be performed in advanced gastric cancer. Therefore, we aimed to verify the non-inferiority of partial omentectomy, oncologic safety compared with total omentectomy via multicenter randomized clinical trial.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Gastric Cancer Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Neoplasms Neoplasms by Site Stomach Diseases Stomach Neoplasms

Age range

20 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically proven adenocarcinoma of the stomach
  • Age between 20 to 85 years old
  • ECOG PS 0-1, ASA class I-III
  • Endoscopically Borrmann type I, II, III
  • Clinical T3 and T4a tumors with or without regional lymph node metastases (cT3N0M0~T4aN3M0)
  • Capable of minimal invasive radical subtotal gastrectomy with R0 resection in preoperative examinations
  • Patients who signed an written consent form approved by the Institutional Review Board(IRB) after receiving sufficient explanations of the contents of the clinical trial
  • Domestic patients who are able to follow up for 3 years after surgery

Exclusion criteria

  • Confirmed distant metastasis in preoperative examinations
  • Confirmed metastasis in abdominal cavity or distant organs during surgery
  • Confirmed no infiltration of the serosa layer or unable to confirm the tumor location during surgery (sT1-2)
  • Confirmed invasion of surrounding organs (sT4b)
  • History of previous gastrectomy or greater omentum related surgery
  • Patients who underwent preoperative treatment (chemotherapy, radiotherapy, or endoscopic submucosal dissection) for recently diagnosed gastric cancer
  • Synchronous or metachronous malignancies, which underwent surgery, chemotherapy or radiotherapy within 5 years
  • Patients judged to be inappropriate for the study by the physician. (ex. Pregnancy)
  • Patients refused to participate after random assignment
  • Surgery is not performed until 30 days after consenting to participate
  • Patients who has participated in another on-going clinical trial, which is related surgical procedures and survival.

Treatment and study plan

Arm I (Total omentectomy),

Procedure

The surgery is performed with minimal invasive surgery, and the range of the surgery is radical gastrectomy and D2 lymph node dissection. Depending on the random assignment, total omentectomy and partial omentectomy (omentum preservation) will be performed for the control group and the experimental group, respectively. Total omentectomy removes whole greater omentum, while partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Other surgical procedures are the same as usual in both groups.

Arm II (Partial omentectomy)

Procedure

The surgery is performed with minimal invasive surgery, and the range of the surgery is radical gastrectomy and D2 lymph node dissection. Depending on the random assignment, total omentectomy and partial omentectomy (omentum preservation) will be performed for the control group and the experimental group, respectively. Total omentectomy removes whole greater omentum, while partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Other surgical procedures are the same as usual in both groups.

Primary outcomes

  1. 3-year relapse free survival

    Time frame: 3 year after surgery

    Verify the non-inferiority of partial omentectomy(omentum preservation) in 3-year relapse free survival(RFS). Kaplan-Meier and log-rank tests will be used.

Secondary outcomes

  1. 3-year overall survival

    Time frame: 3 year after surgery

    To compare surgical outcomes between the partial omentectomy and total omentectomy in patients with advanced gastric cancer, especially clinical T3 and T4a tumors without distant metastasis, who underwent minimal invasive radical gastrectomy and D2 lymph node dissection.

    Clinicopathologic features and surgical outcomes will be analyzed using an paired t-test for continuous variables and the Chi-square test or Fisher's exact test for nominal variables. In the survival analysis, the Kaplan-Meier and log-rank tests will be used. Surgical complications will be graded according to the Clavien-Dindo classification.

  2. Estimated blood loss

    Time frame: during surgery

    To compare surgical outcomes between the partial omentectomy and total omentectomy in patients with advanced gastric cancer, especially clinical T3 and T4a tumors without distant metastasis, who underwent minimal invasive radical gastrectomy and D2 lymph node dissection.

    Clinicopathologic features and surgical outcomes will be analyzed using an paired t-test for continuous variables and the Chi-square test or Fisher's exact test for nominal variables. In the survival analysis, the Kaplan-Meier and log-rank tests will be used. Surgical complications will be graded according to the Clavien-Dindo classification.

  3. Operation time

    Time frame: during surgery

    To compare surgical outcomes between the partial omentectomy and total omentectomy in patients with advanced gastric cancer, especially clinical T3 and T4a tumors without distant metastasis, who underwent minimal invasive radical gastrectomy and D2 lymph node dissection.

    Clinicopathologic features and surgical outcomes will be analyzed using an paired t-test for continuous variables and the Chi-square test or Fisher's exact test for nominal variables. In the survival analysis, the Kaplan-Meier and log-rank tests will be used. Surgical complications will be graded according to the Clavien-Dindo classification.

  4. Post-operative complications (Early, and delayed complication)

    Time frame: 1 month after surgery & 3 year after surgery ( Evaluate 2 times to analyze early complication, and delayed complication respectively)

    To compare surgical outcomes between the partial omentectomy and total omentectomy in patients with advanced gastric cancer, especially clinical T3 and T4a tumors without distant metastasis, who underwent minimal invasive radical gastrectomy and D2 lymph node dissection.

    Clinicopathologic features and surgical outcomes will be analyzed using an paired t-test for continuous variables and the Chi-square test or Fisher's exact test for nominal variables. In the survival analysis, the Kaplan-Meier and log-rank tests will be used. Surgical complications will be graded according to the Clavien-Dindo classification.

  5. Post-operative mortality

    Time frame: 3 months after surgery

    To compare surgical outcomes between the partial omentectomy and total omentectomy in patients with advanced gastric cancer, especially clinical T3 and T4a tumors without distant metastasis, who underwent minimal invasive radical gastrectomy and D2 lymph node dissection.

    Clinicopathologic features and surgical outcomes will be analyzed using an paired t-test for continuous variables and the Chi-square test or Fisher's exact test for nominal variables. In the survival analysis, the Kaplan-Meier and log-rank tests will be used. Surgical complications will be graded according to the Clavien-Dindo classification.

Sponsors and collaborators

Lead sponsor

Gangnam Severance Hospital

Other

Registry information

Official study title

Comparison Between Partial Omentectomy and Total Omentectomy During Minimally Invasive Radical Distal Gastrectomy for Clinical T3 and T4a Gastric Cancer; Multicenter Randomized Clinical Trial (KLASS-10)

Important dates

Study start
2024
Primary completion
2031
Study completion
2031
First posted
Sep 23, 2024
Registry last updated
Sep 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.